# IGA Nephropathy Treatment Market > IGA Nephropathy Treatment Market Research Report By Treatment Type (Immunosuppressive Therapy, Plasmapheresis, Dialysis, Kidney Transplant), By Disease Severity (Mild, Moderate, Severe), By Patient Type (Adult, Pediatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.57% - **2024:** $ 2.05 Billion - **2025:** $ 2.18 Billion - **2035:** $ 4.12 Billion - **Key Players:** Companies such Bristol Myers Squibb (US), Novartis (CH), Pfizer (US), Roche (CH), AbbVie (US), Amgen (US), Sanofi (FR), GSK (GB), Eli Lilly (US) are some of the major participants in the global market. **Report ID:** MRFR/HC/22868-HCR · **Pages:** 128 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** September 10, 2026 **URL:** https://www.marketresearchfuture.com/reports/iga-nephropathy-treatment-market-24490 --- ## Market Summary ## **Iga Nephropathy Treatment Market Overview** As per MRFR analysis, the IGA Nephropathy Treatment Market Size was estimated at 2.05 (USD Billion) in 2024. The IGA Nephropathy Treatment Market Industry is expected to grow from 2.18 (USD Billion) in 2025 to 3.87 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.57% during the forecast period (2025 - 2034). ### **Key Iga Nephropathy Treatment Market Trends Highlighted** The Global Iga Nephropathy Treatment Market is characterized by significant unmet medical needs and a robust pipeline of novel therapies. The rising prevalence of IgA nephropathy, a rare but severe kidney disease, is a key market driver. The growing awareness of the disease and the availability of advanced diagnostic techniques contribute to early detection and timely treatment. Pharmaceutical companies focus on developing innovative therapies, including monoclonal antibodies, immunosuppressants, and anti-inflammatory agents, to address unmet needs in the treatment of IgA nephropathy. These novel treatments aim to improve efficacy and reduce adverse effects, creating opportunities for market growth. Recent trends in the Iga Nephropathy Treatment Market include personalized medicine approaches, biomarker-driven drug development, and the exploration of combination therapies. Personalized medicine allows for tailored treatment strategies based on individual patient characteristics, while biomarker-driven drug development identifies specific targets for therapeutic intervention. Combination therapies aim to enhance treatment efficacy and overcome resistance mechanisms. These trends reflect the ongoing advancements and the dynamic nature of the Iga Nephropathy Treatment Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Iga Nephropathy Treatment Market Drivers** ### **Rising Prevalence of Immunoglobulin A (IgA) Nephropathy** IgA nephropathy is a chronic kidney disease induced by the deposition of IgA immune complexes in the glomeruli. The glomeruli are the tiny filtering units of the kidney structure and are essential for keeping the blood composition correct. Nephropathy is another word for kidney damage. IgA nephropathy is the most prevalent primary glomerulonephritis worldwide, with an incidence of 1 to 2.5 cases per 100,000 populations. The global IgA Nephropathy Treatment Market is driven majorly by the increasing prevalence of IgA Nephropathy. The primary aspects accountable for the increasing occurrence are immune system-mediated abnormalities of kidney function, tremendous genetic propensity, environmental factors, and infectious agents. Moreover, the augmented consciousness about this chronic kidney disease and better diagnosis are also factors that are boosting the market. ### **Technological Advancements in Treatment Options** The Global Iga Nephropathy Treatment Market has witnessed significant technological advancements in recent years, leading to the development of more effective and less invasive treatment options. These advancements include the use of immunosuppressive drugs, such as corticosteroids and mycophenolate mofetil, to suppress the overactive immune response that characterizes IgA nephropathy. Additionally, the advent of biologics, such as rituximab and belimumab, has provided targeted therapies that specifically inhibit the production of IgA antibodies. Furthermore, minimally invasive procedures, such as laparoscopic and robotic-assisted surgery, have reduced the risks and recovery time associated with traditional open surgeries. ### **Growing Demand for Personalized Medicine** Personalized medicine, also known as precision medicine, involves tailoring medical treatment to the individual characteristics of each patient. In the context of IgA nephropathy, personalized medicine approaches consider factors such as genetic makeup, disease severity, and response to previous treatments. The growing demand for personalized medicine in the Global Iga Nephropathy Treatment Market is driven by the need for more effective and targeted therapies that optimize patient outcomes. By understanding the unique molecular and genetic underpinnings of each patient's disease, healthcare providers can select the most appropriate treatment strategies and improve the chances of successful disease management. ## **IGA Nephropathy Treatment Market Segment Insights:** ### **IGA Nephropathy Treatment Market Treatment Type Insights** The Global IGA Nephropathy Treatment Market, particularly in the Treatment Type segment, showcases a robust framework aiming to address various treatment methodologies essential for managing IGA Nephropathy. Within this broader context, the Treatment Type segment is divided into key categories: Immunosuppressive Therapy, Plasmapheresis, Dialysis, and Kidney Transplant, each contributing uniquely to the treatment landscape. #### **Immunosuppressive Therapy** Immunosuppressive Therapy led the market as the dominant treatment option, valued at 0.73 USD Billion in 2023. This significant holding can be attributed to its essential role in reducing inflammation and preventing further kidney damage, often being the preferred choice for patients with moderate to severe disease progression. #### **Plasmapheresis** Following closely, Plasmapheresis was valued at 0.36 USD Billion in 2023, serving as a critical procedure to remove harmful antibodies from the bloodstream. Its efficacy in providing temporary relief and stabilization makes it a significant component of the treatment strategies devised for patients suffering from this condition. #### **Dialysis** Dialysis, valued at 0.45 USD Billion, also played a vital role in managing advanced stages of IGA Nephropathy, particularly for patients experiencing a decline in renal function. This method mitigated the impact of kidney failure by performing the functions of the kidney, thus ensuring patient survival and quality of life. Though not as dominant as Immunosuppressive Therapy, its importance cannot be understated, as it presented a lifeline for those unable to undergo kidney transplants. Lastly, the Kidney Transplant segment, with a valuation of 0.27 USD Billion, signified a potential long-term solution, though it faced challenges related to donor availability and post-operative complications. The relatively lower market size compared to the other therapies reflects both its complexity and the stringent criteria involved in the transplantation process. The Global IGA Nephropathy Treatment Market revenue was influenced by multiple factors, including an increase in disease prevalence, advancements in medical technology, and ongoing research aimed at enhancing treatment efficacy. However, challenges such as high treatment costs and persistent issues surrounding patient adherence also impact market growth. Collectively, the various Treatment Types contribute not only to the individual patient experience but also mark significant milestones in the healthcare industry aimed at improving outcomes for those affected by IGA Nephropathy. The future indicates increasing attention towards refining these therapeutic modalities, as addressing unmet needs in this patient population holds promise for improvements in both survival rates and quality of life, supporting the continuing growth trends within the market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **IGA Nephropathy Treatment Market Disease Severity Insights** Analyzing the disease severity aspect provides vital insights into the segmentation of this market into categories such as Mild, Moderate, and Severe cases of IGA Nephropathy. Each of these categories presents unique treatment challenges and opportunities, influencing the demand for novel therapeutic options. Mild cases often require monitoring and conservative management, while Moderate cases may necessitate more rigorous intervention and emerging therapies. Severe cases dominate the market due to their complexities and the urgent need for effective treatment solutions. The Global IGA Nephropathy Treatment Market data suggests a clear trend towards increasing treatment options tailored to the severity of the disease, supported by advances in medical research. Market growth is also propelled by rising awareness of IGA Nephropathy and the growing emphasis on early diagnosis and targeted therapies, reinforcing the significance of understanding disease severity in shaping treatment protocols and allocation of resources. ### **IGA Nephropathy Treatment Market Patient Type Insights** The market growth is primarily driven by the rising prevalence of IGA nephropathy and increasing awareness regarding the disease. The patient types within this market can broadly be categorized into adults and pediatrics, with adults constituting the majority, influenced by a higher incidence of the disease in this demographic. The adult segment plays a crucial role in market growth as it often requires more advanced treatment options and management regimes. On the other hand, the pediatric segment, although smaller, is gaining attention due to advancements in pediatric care and the long-term impacts of the disease if untreated. With more targeted therapies and a focus on early diagnosis, this segment offers significant opportunities for growth. Overall, the Global IGA Nephropathy Treatment Market data reflects an ongoing trend towards personalization of treatment plans, further influenced by patient type segmentation, which is critical for optimizing care and improving outcomes in both adult and [pediatric Medicine](../../../reports/pediatric-medicine-market-19193) patients. ### **IGA Nephropathy Treatment Market Regional Insights** The Global IGA Nephropathy Treatment Market is experiencing notable growth across regional markets, with North America holding a majority share valued at 0.72 USD Billion in 2023 and expected to reach 1.29 USD Billion by 2032, indicating a significant demand driven by advanced healthcare systems and increased awareness. Europe followed closely with a market valuation of 0.5 USD Billion in 2023, projected to grow to 0.83 USD Billion in 2032, largely supported by robust clinical research and a growing patient population. The Asia Pacific region presented a promising opportunity with a valuation of 0.34 USD Billion in 2023, anticipated to rise to 0.6 USD Billion by 2032, attributed to a rising prevalence of renal diseases and expanding healthcare infrastructure. South America, with a smaller share valued at 0.15 USD Billion, is on a gradual upward trajectory to 0.25 USD Billion in 2032, while the Middle East and Africa segment, valued at 0.1 USD Billion, is seen to grow to 0.23 USD Billion, reflecting an increasing focus on healthcare improvements in these regions. Overall, the Global IGA Nephropathy Treatment Market revenue highlights diverse market dynamics, with each region contributing uniquely to the overall growth and development of the industry. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Iga Nephropathy Treatment Market Key Players And Competitive Insights:** Major players in the Iga Nephropathy Treatment Market are focusing on developing new and innovative therapies to address the unmet medical needs of patients. Leading Iga Nephropathy Treatment Market players are investing heavily in research and development to expand their product portfolios and gain a competitive edge. The IGA Nephropathy Treatment Market development pipeline is robust, with several promising therapies in late-stage clinical trials. These therapies have the potential to significantly improve the treatment outcomes for patients with Iga Nephropathy Treatment Market. The competitive landscape of the Iga Nephropathy Treatment Market is expected to intensify further as new therapies enter the market. Chugai Pharmaceutical Co., Ltd. is a leading Iga Nephropathy Treatment Market player with a strong focus on developing innovative therapies for rare diseases. The company's portfolio includes Renvela (renin inhibitor) and Enspryng (angiotensin II receptor blocker), which are approved for the treatment of the Iga Nephropathy Treatment Market. Chugai Pharmaceutical Co., Ltd. is also developing several other therapies for Iga Nephropathy Treatment Market, including an anti-fibrotic agent and a selective androgen receptor modulator. Bristol Myers Squibb is another major player in the Iga Nephropathy Treatment Market. The company's portfolio includes Kerydin (anakinra), which is approved for the treatment of Iga Nephropathy Treatment Market. Bristol Myers Squibb is also developing several other therapies for Iga Nephropathy Treatment Market, including an anti-inflammatory agent and a JAK inhibitor. ### **Key Companies in the Iga Nephropathy Treatment Market Include:** ## **Iga Nephropathy Treatment Market Developments** The increasing prevalence of IgA nephropathy, rising demand for minimally invasive procedures, and growing awareness about early diagnosis are driving the market growth. Key developments include the FDA approval of Koselugo (selumetinib) for treating IgA nephropathy, as well as ongoing clinical trials evaluating novel therapies such as atacicept and sparsentan. Strategic collaborations and acquisitions, such as the partnership between Kyowa Kirin and Visterra, are also shaping the market landscape. ## **Iga Nephropathy Treatment Market Segmentation Insights** ### **IGA Nephropathy Treatment Market Treatment Type Outlook** ### **IGA Nephropathy Treatment Market Disease Severity Outlook** ### **IGA Nephropathy Treatment Market Patient Type Outlook** ### **IGA Nephropathy Treatment Market Regional Outlook** ## Market Drivers ### Increased Awareness and Education The rising awareness and education regarding Iga nephropathy are pivotal in shaping the Iga Nephropathy Treatment Market. Efforts by healthcare organizations and advocacy groups to educate both patients and healthcare professionals about the disease are gaining momentum. This increased awareness leads to earlier diagnosis and treatment, which is crucial for managing the condition effectively.   Moreover, educational initiatives are likely to empower patients to seek timely medical intervention, thereby expanding the market for treatment options. As more individuals become informed about Iga nephropathy, the demand for effective therapies is expected to rise, further driving the growth of the global industry.   - World Bank health-expenditure data, sourced from the WHO Global Health Expenditure Database, tracks healthcare investment across 2000–2024, supporting greater measurement and planning of healthcare resources. Expanding health-system investment creates opportunities for stronger kidney-disease awareness, screening, diagnosis, and treatment infrastructure. ### Collaborative Research Initiatives Collaborative research initiatives among pharmaceutical companies, academic institutions, and healthcare organizations are fostering innovation in the Iga Nephropathy Treatment Market. These partnerships aim to accelerate the development of new therapies and improve existing treatment protocols.   By pooling resources and expertise, stakeholders can conduct comprehensive studies that enhance understanding of the disease and its treatment. Such collaborations are likely to lead to breakthroughs in therapeutic options, which could significantly impact patient care. As research efforts intensify, the global industry is poised for growth, driven by the introduction of novel treatment strategies and improved patient outcomes.   - PubMed evidence shows that IgA nephropathy research increasingly evaluates targeted approaches and disease progression. A recent study involving 187 IgAN participants found that 57 experienced kidney-function decline during a median 3.1-year follow-up, reinforcing the importance of collaborative research into early risk stratification and disease-modifying therapies. ### Advancements in Treatment Modalities Innovations in treatment modalities are significantly influencing the Iga Nephropathy Treatment Market. Recent advancements in pharmacological therapies, including the introduction of novel immunosuppressants and biologics, have shown promise in managing the disease. These new treatment options are designed to target the underlying mechanisms of Iga nephropathy, potentially improving patient outcomes.   Additionally, the development of personalized medicine approaches allows for tailored therapies based on individual patient profiles, enhancing treatment efficacy. The market is witnessing a shift towards more effective and targeted therapies, which could lead to increased adoption rates among healthcare providers. As a result, the Iga Nephropathy Treatment Industry is expected to experience substantial growth driven by these advancements.   - Novartis' Fabhalta demonstrated a 48% reduction in eGFR decline versus placebo over two years, leading to traditional FDA approval in July 2026. This provides strong evidence of progress toward therapies capable of addressing kidney-function preservation rather than solely managing proteinuria. ### Rising Prevalence of Iga Nephropathy The increasing incidence of Iga nephropathy is a primary driver for the Iga Nephropathy Treatment Market. Recent estimates suggest that the condition affects approximately 2-3 individuals per 100,000 people annually, with a notable rise in cases reported in various regions. This growing prevalence necessitates the development of effective treatment options, thereby propelling market growth.   As healthcare systems strive to address this rising burden, investments in research and innovative therapies are likely to increase. Furthermore, the awareness surrounding Iga nephropathy is gradually improving, leading to earlier diagnosis and treatment. This trend indicates a potential expansion of the patient population seeking therapeutic interventions, which could further stimulate the global Market.   - According to published findings in BMC Public Health, chronic kidney disease cases exceeded 673.7 million globally in 2021, highlighting the expanding patient pool requiring effective nephrology treatments, early diagnostic services, and long-term disease management solutions. ### Growing Investment in Healthcare Infrastructure The expansion of healthcare infrastructure is a crucial driver for the Iga Nephropathy Treatment Market. Governments and private entities are increasingly investing in healthcare facilities and services, particularly in regions with a high prevalence of chronic diseases. This investment is aimed at improving access to diagnostic and treatment options for patients suffering from Iga nephropathy.   Enhanced healthcare infrastructure facilitates better patient management and follow-up care, which is essential for chronic conditions like Iga nephropathy. Furthermore, the establishment of specialized nephrology centers is likely to provide focused care, thereby improving treatment outcomes. As healthcare systems evolve, the global industry stands to benefit from these infrastructural developments.   - The U.S. CDC estimates that approximately 37 million U.S. adults had chronic kidney disease in 2026. CDC also reports that kidney-disease management and screening remain important public-health priorities, supporting continued investment in nephrology services, diagnostic capabilities, and treatment infrastructure. ## Future Outlook The IgA Nephropathy Treatment Industry size is projected to reach USD 4.12 billion by 2035, growing at a CAGR of 6.57%, driven by increasing prevalence and advancements in therapeutic options. **New opportunities:** - Development of personalized medicine approaches for targeted therapies. - - Expansion of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-11001)services for remote patient monitoring. - Investment in AI-driven diagnostic tools for early detection. By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Treatment Type: Immunosuppressive Therapy (Largest) vs. Kidney Transplant (Fastest-Growing) In the IGA Nephropathy Treatment Market, immunosuppressive therapy holds a significant share of 52.4%, as it is the most widely adopted treatment method due to its effectiveness in managing inflammation and immune response. Plasmapheresis follows, providing essential support in severe cases, while Dialysis offers crucial life-sustaining treatment options for patients with advanced kidney failure. [Kidney Transplant](https://www.marketresearchfuture.com/reports/kidney-transplant-market-10678) is gaining traction as an advanced treatment option, transforming the treatment approach for suitable candidates and reshaping the overall market dynamics. Bristol Myers Squibb has a long-standing research presence in immune-mediated kidney disease. Historical clinical research involving BMS-supported nephrology programs contributed to evidence development around IgA nephropathy and immune-modulating approaches, supporting continued pharmaceutical interest in disease mechanisms and treatment innovation. ### By Disease Severity: Mild (Largest) vs. Severe (Fastest-Growing) The IGA Nephropathy Treatment Industry showcases a diverse range of disease severity segments, with mild cases holding the largest share at 48.7%. This segment benefits from a broader patient population, resulting in increased treatment options and a stable demand for therapies. Moderate cases also contribute significantly to the market but are often overshadowed by the larger mild segment. In contrast, the severe segment is rapidly gaining attention due to its rising prevalence and the need for intensive therapies, marking it as a critical area for future growth. Novartis' Fabhalta development targets adults with primary IgA nephropathy at risk of rapid progression. Its 2026 traditional FDA approval demonstrated a 48% reduction in eGFR decline versus placebo, strengthening treatment options designed to intervene before advanced kidney failure develops. ###   ### By Patient Type: Adult (Largest) vs. Pediatric (Fastest-Growing) In the IGA Nephropathy Treatment Market, the patient type segment is primarily dominated by adults, who account for the largest share of the market at 72.8%. This demographic typically presents more severe manifestations of Iga Nephropathy, which drives greater demand for treatment options tailored specifically to their needs. In contrast, pediatric cases, while representing a smaller market share, are increasingly recognized for their potential to grow significantly as awareness and diagnosis improve and as treatment protocols evolve to better address this age group. Adult (Dominant) vs. Pediatric (Emerging) The adult patient segment is characterized by its dominance in the global industry, largely due to the higher prevalence of the disease within this demographic. Adults often experience chronic and more advanced forms of the condition, necessitating a range of treatment interventions, which are well established in the current market. Meanwhile, the pediatric segment is considered emerging, gaining attention as healthcare providers focus on early diagnosis and tailored treatment strategies for younger patients. The shift towards more specialized therapies for children reflects a growing recognition of the unique challenges and treatment responses in this population, driven by advancements in medical research and technology that aim to enhance long-term outcomes. ## Regional Market Share Analysis ### North America : Leading Market for Treatments North America leads in the IGA Nephropathy Treatment Market Size, accounting for over 43.99% of the global revenue in 2024. The region benefits from advanced healthcare infrastructure, high prevalence of chronic kidney diseases, and significant investments in research and development. - The CDC estimates that 37 million U.S. adults had chronic kidney disease in 2026, representing more than 1 in 10 adults. This substantial kidney-disease burden supports demand for advanced nephrology services, diagnostic screening, disease monitoring, and innovative treatments. Regulatory support from agencies like the FDA further catalyzes market growth, ensuring timely access to innovative therapies. The United States is the primary contributor, with a robust presence of key players such as Bristol Myers Squibb, Pfizer, and AbbVie. Canada also plays a significant role, focusing on patient-centric approaches and innovative treatment options. The competitive landscape is characterized by collaborations and partnerships among leading pharmaceutical companies, enhancing the availability of effective treatments. - GE HealthCare generated approximately USD 34.2 billion in 2025 revenue, demonstrating the scale of the healthcare technology ecosystem supporting advanced diagnostics and clinical infrastructure. Its healthcare technology capabilities contribute to an environment conducive to sophisticated disease detection, monitoring, and treatment delivery. ### Europe : Emerging Market with Growth Potential Europe IGA Nephropathy Treatment Market size was valued at USD 0.61 Billion in 2024, making it the second-largest regional market with a 29.81% share. The region's growth is driven by increasing awareness of kidney diseases, supportive healthcare policies, and advancements in medical technology. - EMA designated povetacicept as an orphan medicine for primary IgA nephropathy in March 2025, providing scientific and regulatory support during development. A second IgAN therapy, mezagitamab, also received EU orphan designation in October 2025, demonstrating active European regulatory support for innovative IgAN treatments. Countries like Germany and France are leading the market, supported by favorable regulations and funding for research initiatives aimed at improving patient outcomes. Germany stands out as a key player, with a strong focus on innovative therapies and clinical trials. France and the UK also contribute significantly, with major pharmaceutical companies like Novartis and Roche actively involved in the market. The competitive landscape is marked by strategic collaborations and a focus on personalized medicine, enhancing treatment efficacy and patient care. ### Asia-Pacific : Rapidly Growing Treatment Sector Asia-Pacific is emerging as a significant market for IgA Nephropathy treatment, accounting for about 20% of the global market share. The region's growth is fueled by rising healthcare expenditures, increasing prevalence of kidney disorders, and a growing aging population. Countries like China and Japan are at the forefront, with government initiatives aimed at improving healthcare access and treatment options for chronic diseases. China is rapidly expanding its market presence, with a focus on innovative therapies and collaborations with global pharmaceutical companies. Japan also plays a crucial role, emphasizing research and development in nephrology. The competitive landscape is characterized by a mix of local and international players, enhancing the availability of effective treatments and driving market growth. ### Middle East and Africa : Untapped Market with Challenges The Middle East and Africa region represents an untapped market for IgA Nephropathy treatment, holding approximately 5% of the global market share. The growth potential is significant, driven by increasing awareness of kidney diseases and improving healthcare infrastructure. However, challenges such as limited access to advanced treatments and varying regulatory environments hinder market expansion. Countries like South Africa and the UAE are making strides in addressing these issues. South Africa is emerging as a key player, focusing on enhancing healthcare access and treatment options for chronic kidney diseases. The UAE is also investing in healthcare innovations, aiming to improve patient outcomes. The competitive landscape is still developing, with opportunities for both local and international companies to establish a presence and contribute to market growth. ## Competitive Benchmarking Major players in the Iga Nephropathy Treatment Market are focusing on developing new and innovative therapies to address the unmet medical needs of patients. Leading players are investing heavily in research and development to expand their product portfolios and gain a competitive edge.The development pipeline is robust, with several promising therapies in late-stage clinical trials. These therapies have the potential to significantly improve the treatment outcomes for patients with Iga Nephropathy Treatment Market.    The competitive landscape of the global industry is expected to intensify further as new therapies enter the market.Chugai Pharmaceutical Co., Ltd. is a leading player with a strong focus on developing innovative therapies for rare diseases. The company's portfolio includes Renvela (renin inhibitor) and Enspryng (angiotensin II receptor blocker), which are approved for the treatments.Chugai Pharmaceutical Co., Ltd. is also developing several other therapies for Iga Nephropathy Treatment, including an anti-fibrotic agent and a selective androgen receptor modulator.   Bristol Myers Squibb is another major player in the Iga Nephropathy Treatment Market. The company's portfolio includes Kerydin (anakinra), which is approved for the treatment of Iga Nephropathy Treatment. Bristol Myers Squibb is also developing several other therapies for Iga Nephropathy Treatment, including an anti-inflammatory agent and a JAK inhibitor. ## Recent News & Developments The increasing prevalence of IgA nephropathy, rising demand for minimally invasive procedures, and growing awareness about early diagnosis are driving the market growth. Key developments include the FDA approval of Koselugo (selumetinib) for treating IgA nephropathy, as well as ongoing clinical trials evaluating novel therapies such as atacicept and sparsentan. Strategic collaborations and acquisitions, such as the partnership between Kyowa Kirin and Visterra, are also shaping the market landscape. ## Report Scope | MARKET SIZE 2024 | 2.046(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 2.18(USD Billion) | | MARKET SIZE 2035 | 4.12(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.57% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Bristol Myers Squibb (US), Novartis (CH), Pfizer (US), Roche (CH), AbbVie (US), Amgen (US), Sanofi (FR), GSK (GB), Eli Lilly (US) | | Segments Covered | Treatment Type, Disease Severity, Patient Type, Regional | | Key Market Opportunities | Advancements in targeted therapies and personalized medicine enhance treatment options in the Global Market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Global Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Iga Nephropathy Treatment Market by 2035?** A: The projected market valuation for the Iga Nephropathy Treatment Market is expected to reach 4.12 USD Billion by 2035. **Q: What was the market valuation of the Iga Nephropathy Treatment Industry in 2024?** A: The overall market valuation of the Iga Nephropathy Treatment Industry was 2.046 USD Billion in 2024. **Q: What is the expected CAGR for the Global Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Global Market during the forecast period 2025 - 2035 is 6.57%. **Q: Which treatment type segment had the highest valuation in 2024?** A: In 2024, the Immunosuppressive Therapy segment had the highest valuation at 0.8 USD Billion. **Q: How does the market for pediatric patients compare to adult patients in the Iga Nephropathy Treatment Market?** A: The market for adult patients was valued at 1.225 USD Billion, while the pediatric segment was valued at 0.821 USD Billion in 2024. **Q: What are the projected valuations for the treatment types in 2035?** A: By 2035, the projected valuations for treatment types include Immunosuppressive Therapy at 1.6 USD Billion and Dialysis at 1.0 USD Billion. **Q: Which key players are leading the Iga Nephropathy Treatment Market?** A: Key players in the Iga Nephropathy Treatment Market include Bristol Myers Squibb, Novartis, Pfizer, and Roche. **Q: What was the valuation of the severe disease severity segment in 2024?** A: The severe disease severity segment was valued at 0.614 USD Billion in 2024. **Q: What is the expected growth trend for the Iga Nephropathy Treatment Industry?** A: The Iga Nephropathy Treatment Industry appears to be on a growth trend, with a projected valuation increase to 4.12 USD Billion by 2035. **Q: How does the market for moderate disease severity compare to mild and severe in 2024?** A: In 2024, the moderate disease severity segment was valued at 0.818 USD Billion, which is higher than the mild segment at 0.614 USD Billion but lower than the severe segment at 0.614 USD Billion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/iga-nephropathy-treatment-market-24490*